Synthesis and some Pharmacological Properties of an Immunoactive Lysine-Containing Tetrapeptide


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract

The potentially immunoactive lysine-containing tetrapeptide H-Lys-Ala-Val-Gly-OH was synthesized. The value of using a method based on mixed anhydrides and activated esters to obtain tetrapeptide at high yield was demonstrated. The peptide preparation method was improved by replacing p-nitrophenyl esters at the intermediate stage with N-hydroxysuccinimide esters, yielding a crystalline substance at high purity, and replacing the BOC (tert-butyloxycarbonyl) group for protection with a carbobenzoxy group, which provided for a one-step removal of the protection of both amino groups in mild conditions. Comparative assessment of the immunological activity of the tetrapeptide on the background of immunization with sheep erythrocytes in mice with other lysine-containing tetrapeptides showed it to have more marked immunostimulatory activity. Studies of acute and chronic toxicity demonstrated the absence of toxic activity in the lysine-containing tetrapeptide studied here on s.c. administration to experimental animals. The tetrapeptide corresponded to toxicity class 5, i.e., it was essentially nontoxic.

About the authors

B. M. Kholnazarov

Scientific Center for Expertise in Medicines, Russian Ministry of Health

Email: ndbun@mail.ru
Russian Federation, Moscow

G. M. Bobizoda

S. Aini Tajik State Pedagogical University

Email: ndbun@mail.ru
Tajikistan, Dushanbe

Yu. V. Olefir

Scientific Center for Expertise in Medicines, Russian Ministry of Health

Email: ndbun@mail.ru
Russian Federation, Moscow

A. B. Prokof’ev

I. M. Sechenov First Moscow State Medical Institute, Russian Ministry of Health (Sechenov University); Scientific Center for Expertise in Medicines, Russian Ministry of Health

Email: ndbun@mail.ru
Russian Federation, Moscow; Moscow

M. M. Sapovskii

I. M. Sechenov First Moscow State Medical Institute, Russian Ministry of Health (Sechenov University)

Email: ndbun@mail.ru
Russian Federation, Moscow

V. A. Evteev

Scientific Center for Expertise in Medicines, Russian Ministry of Health

Email: ndbun@mail.ru
Russian Federation, Moscow

N. D. Bunyatyan

I. M. Sechenov First Moscow State Medical Institute, Russian Ministry of Health (Sechenov University); Scientific Center for Expertise in Medicines, Russian Ministry of Health

Author for correspondence.
Email: ndbun@mail.ru
Russian Federation, Moscow; Moscow


Copyright (c) 2018 Springer Science+Business Media, LLC, part of Springer Nature

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies